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The dengue fever (DF) epidemic in 2009 in Sri Lanka resulted in
nearly 370 deaths (1.4% case fatality), mainly adults.1 Although
dengue shock syndrome (DSS) is thought to occur during the
immediate afebrile phase of dengue infection, we encountered
adult patients developing hypotensive DSS during the febrile
phase. Although steroids have been shown to decrease cell
infection rates and inhibit pro-inﬂammatory cytokines,2,3 existing
data do not recommend routine use of steroids in themanagement
of DF.4 However, due to the higher-than-usualmortality during the
current epidemic here, many clinicians used steroids empirically,
usually as rescue medication.
Studies that have assessed the effects of steroids in DF have all
been in children.5 Some show no beneﬁt in established DSS,6,7
while two have shown beneﬁts with high-dose methyl predniso-
lone.8,9 A possible role for steroids in complicated adult DF has not
been investigated.Table 1
Comparisons of clinical, biochemical, and hematological parameters, management and ou
USA). Statistical signiﬁcance was assessed using the Wilcoxon rank sum test for nume
Group A, mean (SD)
Parameters on admission
Age (years) 31 (12)
Sex (M: male, F: female) 23 (M: 7, F:16)
Illness days 3.8 (1.2)/3 (2–6)
Fever (8F) 102 [=38.8 8C] (0.92 [=
Pulse rate (per min) 93 (14)
Systolic BP (supine) mmHg 103 (15)
Diastolic BP (supine) mmHg 67 (9.9)
WBC ( 109/l) 3.5 (1.5)
Hb (g/dl) 14 (2.9)
PCV (dl/l) 42 (8.6)
Platelet count ( 109/l) 70 (63)
Parameters at diagnosis of severe illness
requiring resuscitation
Time since onset of illness (days) 5.6 (1.8)
Time since admission (days) 2.4 (1.6)
Fever (8F) 102 (1)
Pulse rate (per min) 94 (12)
Systolic BP (supine) mmHg 91 (12)
Diastolic BP (supine) mmHg 72 (11)
Hb (g/dl) 14.2 (3.1)
PCV (dl/l) 46 (7.2)
Platelet count ( 109/l) 25 (13)
Pre-resuscitation IV crystalloids (l/24 h) 1 (0.13)
Resuscitation crystalloids, l/h 0.32 (0.098)
Resuscitation FFP (units; 150 ml) 2 (1.1)
Resuscitation platelets (units) 2.3 (2)
Resuscitation colloids l/h 0.036 (0.13)
SGPT (maximum) IU/l 286 (247)
SGOT (maximum) IU/l 814 (1558)
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based on the World Health Organization protocol, and regular
meetings and audits were carried out in order to maintain uniform
standards of care across medical units. In our unit a single dose of
intravenous methyl prednisolone 1 g intravenous over 20 min was
given as rescue medication to highly selected patients who
developed hypotensive DSS (supine systolic blood pressure
<100 mmHg and a postural drop of 20 mmHg with a pulse
pressure 20 mmHg together with the presence of or rapidly
developing ascites or pleural effusions and peripheral vascular
collapse10) during the febrile phase (with no evidence of secondary
bacterial infection), in addition to the currently recommended
management. Clinical and management data of 23 such patients
(group A) were retrospectively compared with 32 comparable
patients from other units who did not receive methyl prednisolone
(group B). The groups were comparable with regard to age, sex,
duration of illness, and clinical and laboratory parameters at the
time of admission and when hypotensive DSS was detected (Table
1). Out of patients with severe DSS, 3/23 died in group A compared
to 15/32 in group B (p = 0.01). Group B required signiﬁcantly more
intensive care treatment and resuscitation ﬂuids (crystalloids,tcome. Statistical analysis was done using Stata 8.2 (Stata Corp., College Station, TX,
ric variables and Fisher’s exact test for categorical variables
Group B, mean (SD) p-Value
34 (13) 0.42
32 (M: 13, F:19)
3.9 (0.71)/3 (2–6) 0.33
17 8C]) 101 [=38.3 8C] (2 [=16 8C]) 0.07
101 (12) 0.20
106 (13) 0.94
66 (14) 0.83
3.8 (1.3) 0.39
13 (0.71) 0.60
42 (4.2) 0.53
36 (30) 0.27
5.9 (1.7) 0.69
2.5 (1.5) 0.7
102 (2.6) 0.4
101 (19) 0.06
87 (38) 0.59
73 (22) 0.24
14.0 (0.8) 0.41
47 (6.3) 0.6
19 (6.2) 0.45
2 (0.6) 0.000
0.51 (0.093) 0.0003
5 (2.4) 0.001
6.8 (3.7) 0.027
0.69 (0.46) 0.0007
762 (1349) 0.24
2964 (3763) 0.04
ses. Published by Elsevier Ltd. All rights reserved.
Table 1 (Continued )
Group A, mean (SD) Group B, mean (SD) p-Value
Myocarditis 18/23 20/32 0.25
Encephalitis 2/23 1/32 0.565
Outcome
Deaths (out of severe DSS) 3/23 15/32 0.010
Deaths (out of all dengue patients) 3/327 15/628 0.15
Time to defervescence (h) 1.4 (2.3) (n=21) 17.2 (6.2) (n=30) 0.000
Hemodynamic stability (h) 5.8 (5.8) (n=20) 18.2 (10.2) (n=17) 0.000
Hematological recovery (days) 2.1 (0.86) (n=20) 3.4 (1.2) (n=17) 0.013
Proportion needing intensive care 8/23 28/32 0.000
Total hospital stay (days) 7.9 (2.6) (n=20) 12.2 (1.3) (n=17) 0.001
SD, standard deviation; BP, blood pressure; WBC, white blood cell count; Hb, hemoglobin; PCV, packed cell volume; IV, intravenous; FFP, fresh frozen plasma; SGPT, serum
glutamic pyruvic transaminase; SGOT, serum glutamic oxaloacetic transaminase; DSS, dengue shock syndrome.
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In survivors, the mean time to hemodynamic stability in group A
was 5.8 h compared to 18.2 h in group B.
These preliminary observations seem to suggest that a timely
single dose of intravenous methyl prednisolone may beneﬁt adult
patients who develop hypotensive DSS during the febrile phase of
DF.We recommend randomized clinical trials to address this issue.
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